Parkinson Disease
📧 Sign up to get email alerts when something new happens for Parkinson Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-03-31Clinical Trial Update: Evaluation of the Infinity Deep Brain Stimulation Electrode Screening Mode Tool [NA]
A completed clinical trial evaluating the Infinity Deep Brain Stimulation electrode screening mode tool, with results posted in 2022.
-
FDA approval · 2022-03-30FDA Approved: IOFLUPANE I 123 — Original Application (Curium US LLC)
The FDA approved IOFLUPANE I-123 (IOFLUPANE I-123) from Curium US LLC in an Original Application as a dopamine transporter imaging agent for…
-
CLINICAL_TRIALS trial_result · 2022-03-29Clinical Trial Update: A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease [Phase 2]
Phase 2 clinical trial evaluating potential screening tools for detecting Parkinson disease.
-
CLINICAL_TRIALS trial_result · 2022-03-23Clinical Trial Update: Bracing for Walking in Parkinson's Disease [NA]
Completed clinical trial investigating gait improvement strategies in Parkinson's disease; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-03-16Clinical Trial Update: A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease [Phase 2]
Phase 2 clinical trial update on ND0612H for advanced Parkinson's disease assessing efficacy, safety, tolerability, and pharmacokinetics.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-03-10Clinical Trial Update: Cannabis Oil for Pain in Parkinson's Disease [Phase 2]
Phase 2 clinical trial investigating cannabis oil for pain in Parkinson's disease is in progress, with status currently unknown.
-
CLINICAL_TRIALS trial_result · 2022-03-02Clinical Trial Update: Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson's Disease [Phase 2, Phase 3]
A Phase 2/3 trial evaluating the effects of PR oxycodone and levodopa versus placebo on central neuropathic pain in Parkinson's disease has …
-
CLINICAL_TRIALS trial_result · 2022-02-28Clinical Trial Update: A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation [Phase 2]
Phase 2 study of Venglustat (GZ/SAR402671) in Parkinson's disease patients with a GBA mutation was terminated; results posted in 2022.
-
FDA approval · 2022-02-23FDA Approved: APOMORPHINE HYDROCLORIDE — Original Application (TruPharma, LLC)
FDA approved a generic apomorphine hydrochloride product under Original Application (ANDA212025) from TruPharma, LLC for use in Parkinson's …
-
EMA withdrawal · 2022-02-18EMA Withdrawn: Leganto (rotigotine) — UCB Pharma S.A.
Leganto (rotigotine) has been withdrawn from the market by UCB Pharma S.A., affecting treatment areas including restless legs syndrome and P…
-
CLINICAL_TRIALS trial_result · 2022-02-08Clinical Trial Update: Utilization of Target Ranges to Treat Parkinson's Disease With the PKG [NA]
Clinical trial update indicates termination for a Parkinson's disease study evaluating target ranges with PKG technology; results posted.
-
FDA approval · 2022-02-03FDA Approved: PRAMIPEXOLE DIHYDROCHLORIDE — Original Application (Ingenus Pharmaceuticals, LLC)
The FDA approved Ingenus Pharmaceuticals' original Abbreviated New Drug Application for pramipexole dihydrochloride (generic), a dopamine ag…
-
CLINICAL_TRIALS trial_result · 2022-02-01Clinical Trial Update: Adaptive Closed Loop Neuromodulation and Neural Signatures of Parkinson's Disease [NA]
Clinical trial update on adaptive closed-loop neuromodulation and neural signatures for Parkinson's disease; status completed with results p…
-
FDA approval · 2022-01-25FDA Approved: CARBIDOPA, LEVODOPA AND ENTACAPONE — Original Application (Rising Pharma Holdings, Inc.)
FDA approved Rising Pharma's original application for a generic fixed-dose combination of carbidopa, levodopa, and entacapone. This approval…
-
EMA approval · 2022-01-19EMA Refused: Nouryant (Istradefylline) — Kyowa Kirin Holdings B.V.
The EMA refused approval for Nouryant (istradefylline) for Parkinson's disease from Kyowa Kirin Holdings B.V.
-
CLINICAL_TRIALS trial_result · 2022-01-19Clinical Trial Update: ExAblate Transcranial MRgFUS of the Globus Pallidum for Treatment of Parkinson's Disease [NA]
A completed clinical trial evaluating ExAblate Transcranial MRgFUS targeting the globus pallidum for Parkinson's disease; results posted in …
-
CLINICAL_TRIALS trial_result · 2022-01-11Clinical Trial Update: Auricular Muscle Zone Stimulation for Parkinson Disease [Phase 2]
Phase 2 clinical trial evaluating auricular muscle zone stimulation for Parkinson disease has completed.
-
CLINICAL_TRIALS trial_result · 2022-01-10Clinical Trial Update: 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety [Phase 3]
Phase 3 clinical trial evaluating 18F-DOPA PET imaging for biodistribution and safety.
-
FDA approval · 2022-01-04FDA Approved: ENTACAPONE — Original Application (Alembic Pharmaceuticals Limited)
FDA approves Alembic Pharmaceuticals Limited's original application for Entacapone. Entacapone is a COMT inhibitor used as an adjunct to lev…
-
CLINICAL_TRIALS trial_result · 2021-12-21Clinical Trial Update: Evaluation of Using Vibrotactile Coordinated Reset for Management of Parkinson's Disease [NA]
A terminated clinical trial evaluating vibrotactile coordinated reset for management of Parkinson's disease; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-12-06Clinical Trial Update: Real-PD Trial: Development of Clinical Prognostic Models for Parkinson's Disease
Clinical trial update reporting completion of the Real-PD study on prognostic models for Parkinson's disease with posted results.
-
CLINICAL_TRIALS trial_result · 2021-11-23Clinical Trial Update: Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease [Phase 2]
Phase 2 clinical trial evaluating BIIB054 in Parkinson's disease was terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2021-11-23Clinical Trial Update: A Randomized, Double-Blind, Placebo-Controlled Study of Droxidopa for Fatigue in Parkinson's Disease [Phase 4]
Phase 4 randomized trial of droxidopa for fatigue in Parkinson's disease was terminated.
-
CLINICAL_TRIALS trial_result · 2021-11-23Clinical Trial Update: An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's Disease [Phase 4]
Open-label Phase 4 trial updating tolerability and exploratory efficacy of zonisamide for dyskinesias in Parkinson's disease; study suspende…
-
FDA approval · 2021-11-18FDA Approved: RASAGILINE — Original Application (Carnegie Pharmaceuticals LLC)
The FDA approved Carnegie Pharmaceuticals' original application for Rasagiline (rasagiline mesylate), a generic monoamine oxidase-B inhibito…